Related references
Note: Only part of the references are listed.Cancer statistics, 2022
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2022)
Immune-based combinations for metastatic triple negative breast cancer in clinical trials: current knowledge and therapeutic prospects
Alessandro Rizzo et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2022)
Biomarkers for breast cancer immunotherapy: PD-L1, TILs, and beyond
Alessandro Rizzo et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2022)
Ladiratuzumab vedotin for metastatic triple negative cancer: preliminary results, key challenges, and clinical potential
Alessandro Rizzo et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2022)
An Invasive Disease Event-Free Survival Analysis to Investigate Ki67 Role with Respect to Breast Cancer Patients' Age: A Retrospective Cohort Study
Raffaella Massafra et al.
CANCERS (2022)
Olaparib monotherapy as primary treatment in unselected triple negative breast cancer
H. P. Eikesdal et al.
ANNALS OF ONCOLOGY (2021)
Deep exploration of PARP inhibitors in breast cancer: monotherapy and combination therapy
Zheling Chen et al.
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH (2021)
Role of Immunotherapy in Triple-Negative Breast Cancer
Tanya E. Keenan et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2020)
Akt-targeted therapy as a promising strategy to overcome drug resistance in breast cancer – A comprehensive review from chemotherapy to immunotherapy
Parham Jabbarzadeh Kaboli et al.
PHARMACOLOGICAL RESEARCH (2020)
Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial
Veronique Dieras et al.
LANCET ONCOLOGY (2020)
Triple-negative breast cancer molecular subtyping and treatment progress
Li Yin et al.
BREAST CANCER RESEARCH (2020)
PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer
Constantia Pantelidou et al.
CANCER DISCOVERY (2019)
Advances in the systemic treatment of triple-negative breast cancer
J. M. Lebert et al.
CURRENT ONCOLOGY (2018)
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial
Sibylle Loibl et al.
LANCET ONCOLOGY (2018)
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial
Andrew Tutt et al.
NATURE MEDICINE (2018)
Triple-Negative Breast Cancer Who Should Receive Neoadjuvant Chemotherapy?
Lubna N. Chaudhary et al.
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA (2018)
Mechanisms of PARP inhibitor sensitivity and resistance
Alan D. D'Andrea
DNA REPAIR (2018)
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Jennifer K. Litton et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Mark Robson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer
Shivaani Kummar et al.
INVESTIGATIONAL NEW DRUGS (2016)
Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer
H. S. Rugo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
SOLTI NeoPARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer
Antonio Llombart-Cussac et al.
BREAST CANCER RESEARCH AND TREATMENT (2015)
An update on PARP inhibitors-moving to the adjuvant setting
Amir Sonnenblick et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2015)
Phase III Study of Iniparib Plus Gemcitabine and Carboplatin Versus Gemcitabine and Carboplatin in Patients With Metastatic Triple-Negative Breast Cancer
Joyce O'Shaughnessy et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
GRADE guidelines: A new series of articles in the Journal of Clinical Epidemiology
Gordon H. Guyatt et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2011)
Adverse bone effects during pharmacological breast cancer therapy
Nina H. Bjarnason et al.
ACTA ONCOLOGICA (2008)
Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients - A single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results Database
Gloria J. Morris et al.
CANCER (2007)
Triple-negative breast cancer: Clinical features and patterns of recurrence
Rebecca Dent et al.
CLINICAL CANCER RESEARCH (2007)
Share Paper
